Synaptogenix, Inc. operates as a biopharmaceutical entity, actively advancing multiple product candidates through both preclinical and clinical development stages. The company's primary focus involves establishing a therapeutic platform centered on Bryostatin-1, a key drug candidate, primarily for the treatment of Alzheimer's disease. Additionally, Synaptogenix is exploring Bryostatin's potential applications for various other neurodegenerative or cognitive disorders and dysfunctions, including fragile X syndrome, multiple sclerosis, and Niemann-Pick type C disease.